Innovator Equity Dual Directional 15 Buffer ETF - September

21.32

+0.12510.59%

Volume:8.16K

Turnover:173.52K

Market Cap:52.24M

PE:- -

High:21.32

Open:21.23

Low:21.23

Close:21.20

52wk High:21.35

52wk Low:20.39

Shares:2.45M

Float Shares:2.45M

Volume Ratio:1.90

T/O Rate:0.33%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

GlobeNewswire

·

Dec 09, 2025

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

GlobeNewswire

·

Nov 25, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DDFS"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DDFS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DDFS\",,,,,undefined,":{"symbol":"DDFS","market":"US","secType":"STK","nameCN":"Innovator Equity Dual Directional 15 Buffer ETF - September","latestPrice":21.324,"timestamp":1770411600000,"preClose":21.1989,"halted":0,"volume":8158,"delay":0,"changeRate":0.005901249593139424,"floatShares":2450000,"shares":2450000,"eps":0,"marketStatus":"Market Closed","change":0.1251,"latestTime":"02-06 16:00:00 EST","open":21.23,"high":21.324,"low":21.23,"amount":173524.9952,"amplitude":0.004434,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":21.1989,"sharesOutstanding":2450000,"nav":21.18,"aum":51891000,"bidAskSpread":0,"volumeRatio":1.896415524530774},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DDFS\",,,,,undefined,":{"symbol":"DDFS","floatShares":2450000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.896415524530774,"shares":2450000,"dividePrice":0,"high":21.324,"amplitude":0.004434,"preClose":21.1989,"low":21.23,"week52Low":20.39,"pbRate":"--","week52High":21.3499,"institutionHeld":0,"latestPrice":21.324,"eps":0,"divideRate":0,"volume":8158,"delay":0,"ttmEps":0,"open":21.23,"prevYearClose":21.19,"prevWeekClose":21.295,"prevMonthClose":21.295,"prevQuarterClose":21.19,"fiveDayClose":21.295,"twentyDayClose":21.2502,"sixtyDayClose":20.95},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DDFS\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DDFS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DDFS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DDFS\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2590456673","title":"1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years","url":"https://stock-news.laohu8.com/highlight/detail?id=2590456673","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590456673?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:15","pubTimestamp":1765282500,"startTime":"0","endTime":"0","summary":"Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1 KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202238/0/en/1-in-4-metastatic-breast-cancer-patients-treated-with-Novartis-Kisqali-remain-progression-free-beyond-4-years.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4195","BK4581","BK4109","LU2092937221.SGD","LU2229751404.USD","BK4590","LU2413666426.HKD","PFS","IE00BN0W2W23.USD","BK4211","IE00BN0W2T93.GBP","BK4567","BK4585","LU1543694498.USD","A","IE00BN0W2V16.EUR","ET","LU0347712357.USD","LU1165135440.EUR","LU1721428933.USD","EBC","BK4561","DDFS","OS","LU2413666699.HKD","BK4588","BK4144","BK4097","FUL","LU2089279066.USD","LU2041044095.USD"],"gpt_icon":0},{"id":"2586441294","title":"Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS","url":"https://stock-news.laohu8.com/highlight/detail?id=2586441294","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586441294?lang=en_us&edition=fundamental","pubTime":"2025-11-25 14:15","pubTimestamp":1764051300,"startTime":"0","endTime":"0","summary":"Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix data across clinical and real-world settings off","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194022/0/en/Novartis-data-underscore-pioneering-scientific-innovation-in-Hematology-and-Oncology-at-ASH-and-SABCS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","LU2463526074.USD","BK4195","BK4590","BC","ITP","BK4190","BK4144","FUL","BK4097","IS","BK4581","OS","DDFS","BK4561","EBC","ET","BK4211","BK4109","BK4199","ASC","BK4585","PFS","BK4588"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DDFS\",params:#limit:6,delay:false,,,undefined,":[]}}